Safety And Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir Fixed-Dose Combination for 12 Weeks in Adults Who Participated in a Prior Gilead-Sponsored HCV Treatment Study

Clinical trial NCT03118843 · COMPLETED

Trial details

NCT number

NCT03118843

Sponsor

Gilead Sciences

Status

COMPLETED

Phase

Phase 3

Study type

INTERVENTIONAL

Start date

2017-04-25

Primary completion

2018-03-19

Enrollment

31

View on ClinicalTrials.gov